(Q37762226)

22 August 2017

1 reference

title

Tumor immune therapy: lessons from infection and implications for cancer - can IL-7 help overcome immune inhibitory networks? (English)

1 reference

22 August 2017

1 reference

Marc Pellegrini

1

0 references

author name string

Tak W Mak

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

European Journal of Immunology

22 August 2017

published in

1 reference

22 August 2017

volume

40

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1852-1861

1 reference

Redefining chronic viral infection

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

NF-kappaB: linking inflammation and immunity to cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

The adaptive immune response to sporadic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Pattern recognition receptors and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Negative selection and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Pattern recognition receptors of innate immunity and their application to tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Unique human tumor antigens: immunobiology and use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Behavior of immune players in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

The role of myeloid cells in the promotion of tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

CD4+ T-regulatory cells: toward therapy for human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

SOCS proteins, cytokine signalling and immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

NFAT Binding and Regulation of T Cell Activation by the Cytoplasmic Scaffolding Homer Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Egr-2 and Egr-3 are negative regulators of T cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-7 promotes T cell proliferation through destabilization of p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Can NK cells be a therapeutic target in human cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Functions of γC cytokines in immune homeostasis: current and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

New insights into the regulation of T cells by gamma(c) family cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

A review of recent findings involving interleukin-2-based cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Tolerance, not immunity, crucially depends on IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin 15 controls the generation of the restricted T cell receptor repertoire of gamma delta intestinal intraepithelial lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

A critical role for IL-21 in regulating immunoglobulin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin-21 activates human natural killer cells and modulates their surface receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

A vital role for interleukin-21 in the control of a chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21R on T cells is critical for sustained functionality and control of chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21 is required to control chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Tumor-specific Th17-polarized cells eradicate large established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Use of tumour-responsive T cells as cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Dendritic-cell- and peptide-based vaccination strategies for glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Targets of protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

The allogeneic graft-versus-cancer effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Use of natural killer cells in hematopoetic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Novel function for interleukin-7 in dendritic cell development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

NK cells recognize and kill human glioblastoma cells with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Dendritic cells prime natural killer cells by trans-presenting interleukin 15

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

Immune modulation with interleukin-21

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040603

7 January 2021

Identifiers

DOI

10.1002/EJI.201040603

1 reference

22 August 2017

1 reference